Purple Book reference family · 351(a) biologic
Influenza A [H5] Monovalent Vaccine, Adjuvanted (Arepanrix)
Influenza A [H5] Monovalent Vaccine, Adjuvanted is an FDA-licensed reference biologic from ID Biomedical Corporation of Quebec.
351(a) biologicBLA 125419 ID Biomedical Corporation of Quebec
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2013
Reference product
Originator biologic
351(a)BLA 125419
Arepanrix Influenza A [H5] Monovalent Vaccine, Adjuvanted
ID Biomedical Corporation of Quebec
View full reference-product record- Approved
- Marketing
- Disc
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference Influenza A [H5] Monovalent Vaccine, Adjuvanted product.
12 yr 10 mo ago
Influenza A [H5] Monovalent Vaccine, Adjuvanted: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for Influenza A [H5] Monovalent Vaccine, Adjuvanted.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
